VisionGateAI Awarded Prestigious Andy Hill CARE Fund Grant to Advance Early-Stage Lung Cancer Detection

VisionGateAI reports that it has received a major grant from the Andy Hill Cancer Research Endowment (CARE) Fund to accelerate the clinical development of its patented Cell-CT™ technology and the LuCED® test. This funding specifically targets the expansion of early-stage lung cancer detection in underserved rural communities where healthcare disparities severely impact survival rates.

The grant supports the advanced development of the LuCED test, a home-collected sputum screening test designed to dramatically improve early-stage cancer detection accuracy and cost-effectiveness. Published clinical study data demonstrates that the technology achieves a 94% sensitivity in detecting stage 1 lung cancer that is typically asymptomatic and highly curable by surgery. This unprecedented performance represents a potential paradigm shift in patient management, transforming how high-risk and rural populations are screened.

“We are deeply grateful for the critical and timely support from the Andy Hill CARE Fund,” said VisionGateAI’s Founder and CEO, Dr. Alan Nelson. “This non-dilutive grant validates our technology’s potential to reduce lung cancer mortality on a systemic level and requires a 1:1 match from out-of-state funding sources to further fuel our clinical roadmap.”

This funding positions VisionGateAI to scale its non-invasive screening capabilities, enabling early detection delivered directly to patients at home and closing the care gap for geographically isolated populations. Please see the award announcement and further information that is available from these website links:
https://www.wacarefund.org/grant-awards/optimization-of-the-non-invasive-luced-test-for-detecting-early-stage-lung-cancer/